Skip to main content
Erschienen in: Herzschrittmachertherapie + Elektrophysiologie 2/2021

06.04.2021 | Schwerpunkt

Atrial fibrillation during pregnancy: a 9-month period with limited options

verfasst von: Konstantinos Iliodromitis, MD, Jacek Kociszewski, MD, Priv. Doz. Dr. Harilaos Bogossian, MD

Erschienen in: Herzschrittmachertherapie + Elektrophysiologie | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Pregnancy is a physiological condition with reversible hemodynamic, neurohormonal and coagulation changes to the maternal body during this 9‑month period. The occurrence of atrial fibrillation (AF) is altogether rare among pregnant women, but necessitates immediate treatment und further work-up. Despite numerous pharmacological and invasive therapeutic modalities for AF in non-pregnant patients, very few options are considered safe enough for the fetus and the mother during pregnancy. Commonly used medications such as beta blockers, calcium channel antagonists, antiarrhythmic drugs and anticoagulation therapy must be carefully individualized according to the week of gestation and possible underlying comorbidities of the mother, thus highlighting the importance of an interdisciplinary evaluation by a cardiologist and a gynecologist. The current review summarizes the existing knowledge and treatment options for AF in pregnancy and suggests a simplified algorithm for this clinical constellation.
Literatur
1.
Zurück zum Zitat Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129(8):837–847PubMed Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129(8):837–847PubMed
3.
Zurück zum Zitat Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE (2016) Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 13:321–332PubMedPubMedCentral Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE (2016) Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 13:321–332PubMedPubMedCentral
4.
Zurück zum Zitat Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, Johnson A, Osorio F, Goldberg C, Moore LG, Dahms T, Schrier RW (1998) Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 54:2056–2063PubMed Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, Johnson A, Osorio F, Goldberg C, Moore LG, Dahms T, Schrier RW (1998) Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 54:2056–2063PubMed
5.
Zurück zum Zitat Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM (2014) A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens 32:849–856PubMed Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM (2014) A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens 32:849–856PubMed
6.
Zurück zum Zitat Bader RA, Bader ME, Rose DF, Braunwald E (1955) Hemodynamics at rest and during exercise in normal pregnancy as studies by cardiac catheterization. J Clin Invest 34:1524–1536PubMedPubMedCentral Bader RA, Bader ME, Rose DF, Braunwald E (1955) Hemodynamics at rest and during exercise in normal pregnancy as studies by cardiac catheterization. J Clin Invest 34:1524–1536PubMedPubMedCentral
7.
Zurück zum Zitat Robson SC, Hunter S, Boys RJ, Dunlop W (1989) Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 256(pt 2):H1060–H1065PubMed Robson SC, Hunter S, Boys RJ, Dunlop W (1989) Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 256(pt 2):H1060–H1065PubMed
8.
9.
Zurück zum Zitat Jarvis SS, Shibata S, Bivens TB, Okada Y, Casey BM, Levine BD, Fu Q (2012) Sympathetic activation during early pregnancy in humans. J Physiol 590(pt 15):3535–3543PubMedPubMedCentral Jarvis SS, Shibata S, Bivens TB, Okada Y, Casey BM, Levine BD, Fu Q (2012) Sympathetic activation during early pregnancy in humans. J Physiol 590(pt 15):3535–3543PubMedPubMedCentral
10.
Zurück zum Zitat Greenwood JP, Scott EM, Stoker JB, Walker JJ, Mary DA (2001) Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 104:2200–2204PubMed Greenwood JP, Scott EM, Stoker JB, Walker JJ, Mary DA (2001) Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 104:2200–2204PubMed
11.
Zurück zum Zitat Chesley LC (1972) Plasma and red cell volumes during pregnancy. Am J Obstet Gynecol 112:440–450PubMed Chesley LC (1972) Plasma and red cell volumes during pregnancy. Am J Obstet Gynecol 112:440–450PubMed
12.
Zurück zum Zitat Pritchard JA (1965) Changes in the blood volume during pregnancy and delivery. Anesthesiology 26:393–399PubMed Pritchard JA (1965) Changes in the blood volume during pregnancy and delivery. Anesthesiology 26:393–399PubMed
13.
14.
Zurück zum Zitat Robson SC, Hunter S, Moore M, Dunlop W (1987) Haemodynamic changes during the puerperium: a Doppler and M‑mode echocardiographic study. Br J Obstet Gynaecol 94:1028–1039PubMed Robson SC, Hunter S, Moore M, Dunlop W (1987) Haemodynamic changes during the puerperium: a Doppler and M‑mode echocardiographic study. Br J Obstet Gynaecol 94:1028–1039PubMed
15.
Zurück zum Zitat Umar S, Nadadur R, Iorga A, Amjedi M, Matori H, Eghbali M (2012) Cardiac structural and hemodynamic changes associated with physiological heart hypertrophy of pregnancy are reversed postpartum. J Appl Physiol (1985) 113:1253–1259 Umar S, Nadadur R, Iorga A, Amjedi M, Matori H, Eghbali M (2012) Cardiac structural and hemodynamic changes associated with physiological heart hypertrophy of pregnancy are reversed postpartum. J Appl Physiol (1985) 113:1253–1259
16.
Zurück zum Zitat Ducas RA, Elliott JE, Melnyk SF, Premecz S, daSilva M, Cleverley K, Wtorek P, Mackenzie GS, Helewa ME, Jassal DS (2014) Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac Hemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study. J Cardiovasc Magn Reson 16:1PubMedPubMedCentral Ducas RA, Elliott JE, Melnyk SF, Premecz S, daSilva M, Cleverley K, Wtorek P, Mackenzie GS, Helewa ME, Jassal DS (2014) Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac Hemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study. J Cardiovasc Magn Reson 16:1PubMedPubMedCentral
17.
Zurück zum Zitat Gowda RM, Punukollu G, Khan IA, Wilbur SL, Navarro VS, Vasavada BC, Sacchi TJ (2003) Lone atrial fibrillation during pregnancy. Int J Cardiol 88(1):123–124PubMed Gowda RM, Punukollu G, Khan IA, Wilbur SL, Navarro VS, Vasavada BC, Sacchi TJ (2003) Lone atrial fibrillation during pregnancy. Int J Cardiol 88(1):123–124PubMed
18.
Zurück zum Zitat Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 37:2893–2962PubMed Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 37:2893–2962PubMed
19.
Zurück zum Zitat Bateman BT, Heide-Jorgensen U, Einarsdottir K et al (2018) beta-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med 169:665–673PubMedPubMedCentral Bateman BT, Heide-Jorgensen U, Einarsdottir K et al (2018) beta-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med 169:665–673PubMedPubMedCentral
20.
Zurück zum Zitat Bergman JEH, Lutke LR, Gans ROB et al (2018) Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. Drug Saf 41:415–427PubMed Bergman JEH, Lutke LR, Gans ROB et al (2018) Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. Drug Saf 41:415–427PubMed
21.
Zurück zum Zitat Duan L, Ng A, Chen W et al (2017) beta-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 177:885–887PubMedPubMedCentral Duan L, Ng A, Chen W et al (2017) beta-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 177:885–887PubMedPubMedCentral
22.
Zurück zum Zitat Yakoob MY, Bateman BT, Ho E et al (2013) The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension 62:375–381PubMed Yakoob MY, Bateman BT, Ho E et al (2013) The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension 62:375–381PubMed
23.
Zurück zum Zitat Pruyn SC, Phelan JP, Buchanan GC (1979) Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol 135:485–489PubMed Pruyn SC, Phelan JP, Buchanan GC (1979) Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol 135:485–489PubMed
24.
Zurück zum Zitat Duan L, Ng A, Chen W, Spencer HT, Lee MS (2018) Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich) 20:1603–1609 Duan L, Ng A, Chen W, Spencer HT, Lee MS (2018) Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich) 20:1603–1609
25.
Zurück zum Zitat Lydakis C, Lip GY, Beevers M, Beevers DG (1999) Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541–547PubMed Lydakis C, Lip GY, Beevers M, Beevers DG (1999) Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541–547PubMed
26.
27.
Zurück zum Zitat Wright JM, Page RL, Field ME (2015) Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther 13:1433–1444PubMed Wright JM, Page RL, Field ME (2015) Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther 13:1433–1444PubMed
28.
Zurück zum Zitat Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G (1996) The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 174(3):823–828PubMed Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G (1996) The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 174(3):823–828PubMed
29.
Zurück zum Zitat Davis RL, Eastman D, McPhillips H et al (2011) Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20:138–145PubMed Davis RL, Eastman D, McPhillips H et al (2011) Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20:138–145PubMed
31.
Zurück zum Zitat Rotmensch HH, Elkayam U, Frishman W (1983) Antiarrhythmic drug therapy during pregnancy. Ann Intern Med 98:487–497PubMed Rotmensch HH, Elkayam U, Frishman W (1983) Antiarrhythmic drug therapy during pregnancy. Ann Intern Med 98:487–497PubMed
32.
Zurück zum Zitat Chow T, Galvin J, McGovern B (1998) Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 82:58i–62iPubMed Chow T, Galvin J, McGovern B (1998) Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 82:58i–62iPubMed
33.
Zurück zum Zitat Hill GD, Kovach JR, Saudek DE et al (2017) Transplacental treatment of fetal tachycardia: a systematic review and meta-analysis. Prenat Diagn 37:1076–1083PubMed Hill GD, Kovach JR, Saudek DE et al (2017) Transplacental treatment of fetal tachycardia: a systematic review and meta-analysis. Prenat Diagn 37:1076–1083PubMed
34.
Zurück zum Zitat Wright JM, Page RL, Field ME (2015) Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther 13:1433–1444PubMed Wright JM, Page RL, Field ME (2015) Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther 13:1433–1444PubMed
35.
Zurück zum Zitat Oudijk MA, Michon MM, Kleinman CS et al (2000) Sotalol in the treatment of fetal dysrhythmias. Circulation 101:2721–2726PubMed Oudijk MA, Michon MM, Kleinman CS et al (2000) Sotalol in the treatment of fetal dysrhythmias. Circulation 101:2721–2726PubMed
36.
Zurück zum Zitat Magee LA, Downar E, Sermer M et al (1995) Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 172:1307–1311PubMed Magee LA, Downar E, Sermer M et al (1995) Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 172:1307–1311PubMed
37.
Zurück zum Zitat Ovadia M, Brito M, Hoyer GL, Marcus FI (1994) Human experience with amiodarone in the embryonic period. Am J Cardiol 73:316–317PubMed Ovadia M, Brito M, Hoyer GL, Marcus FI (1994) Human experience with amiodarone in the embryonic period. Am J Cardiol 73:316–317PubMed
38.
Zurück zum Zitat Bremme KA (2003) Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 16(2):153–168PubMed Bremme KA (2003) Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 16(2):153–168PubMed
39.
Zurück zum Zitat Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e691S–e736SPubMedPubMedCentral Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e691S–e736SPubMedPubMedCentral
40.
Zurück zum Zitat Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM (2012) Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 163(2):154–159PubMed Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM (2012) Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 163(2):154–159PubMed
41.
Zurück zum Zitat Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M et al (2013) High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol 132(1):131–139PubMed Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M et al (2013) High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol 132(1):131–139PubMed
42.
Zurück zum Zitat Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S et al (2013) Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 11(2):270–281PubMed Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S et al (2013) Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 11(2):270–281PubMed
43.
Zurück zum Zitat Chaudhary RK, Nepal C, Khanal N, Pathak R, Giri S, Bhatt VR (2015) Management and outcome of heparin-induced thrombocytopenia in pregnancy: a systematic review. Cardiovasc Hematol Agents Med Chem 13(2):92–97PubMed Chaudhary RK, Nepal C, Khanal N, Pathak R, Giri S, Bhatt VR (2015) Management and outcome of heparin-induced thrombocytopenia in pregnancy: a systematic review. Cardiovasc Hematol Agents Med Chem 13(2):92–97PubMed
44.
Zurück zum Zitat Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93(1):63–69PubMed Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93(1):63–69PubMed
45.
Zurück zum Zitat Raivio KO, Ikonen E, Saarikoski S (1977) Fetal risks due to warfarin therapy during pregnancy. Acta Paediatr Scand 66(6):735–739PubMed Raivio KO, Ikonen E, Saarikoski S (1977) Fetal risks due to warfarin therapy during pregnancy. Acta Paediatr Scand 66(6):735–739PubMed
46.
Zurück zum Zitat Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33(6):1637–1641PubMed Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33(6):1637–1641PubMed
47.
Zurück zum Zitat Khamooshi AJ, Kashfi F, Hoseini S, Tabatabaei MB, Javadpour H, Noohi F (2007) Anticoagulation for prosthetic heart valves in pregnancy. Is there an answer? Asian Cardiovasc Thorac Ann 15(6):493–496PubMed Khamooshi AJ, Kashfi F, Hoseini S, Tabatabaei MB, Javadpour H, Noohi F (2007) Anticoagulation for prosthetic heart valves in pregnancy. Is there an answer? Asian Cardiovasc Thorac Ann 15(6):493–496PubMed
48.
Zurück zum Zitat Bapat P, Pinto LS, Lubetsky A, Aleksa K, Berger H, Koren G et al (2016) Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost 14(7):1436–1441PubMed Bapat P, Pinto LS, Lubetsky A, Aleksa K, Berger H, Koren G et al (2016) Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost 14(7):1436–1441PubMed
49.
Zurück zum Zitat Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G (2015) Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 213(5):710.e1–710.e6 Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G (2015) Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 213(5):710.e1–710.e6
50.
Zurück zum Zitat Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H et al (2014) Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 123(6):1256–1261PubMed Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H et al (2014) Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 123(6):1256–1261PubMed
51.
Zurück zum Zitat Pacheco LD, Hankins GDV, Saad AF, Saade GR (2019) Acute management of ischemic stroke during pregnancy. Obstet Gynecol 133(5):933–939PubMed Pacheco LD, Hankins GDV, Saad AF, Saade GR (2019) Acute management of ischemic stroke during pregnancy. Obstet Gynecol 133(5):933–939PubMed
52.
Zurück zum Zitat Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL (2019) Guidelines for the early management of patients with acute Ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50(12):e344–e418PubMed Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL (2019) Guidelines for the early management of patients with acute Ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50(12):e344–e418PubMed
53.
Zurück zum Zitat Zei PC, Quadros KK, Clopton P, Thosani A, Ferguson J, Brodt C, O’Riordan G, Ramsis M, Mitra R, Baykaner T (2020) Safety and efficacy of minimal- versus zero-fluoroscopy radiofrequency catheter ablation for atrial fibrillation: a multicenter, prospective study. J Innov Card Rhythm Manag 11(11):4281–4291PubMedPubMedCentral Zei PC, Quadros KK, Clopton P, Thosani A, Ferguson J, Brodt C, O’Riordan G, Ramsis M, Mitra R, Baykaner T (2020) Safety and efficacy of minimal- versus zero-fluoroscopy radiofrequency catheter ablation for atrial fibrillation: a multicenter, prospective study. J Innov Card Rhythm Manag 11(11):4281–4291PubMedPubMedCentral
54.
Zurück zum Zitat Li MM, Sang CH, Jiang CX, Guo XY, Li SN, Wang W, Zhao X, Tang RB, Long DY, Gao H, Dong JZ, Du X, Ma CS (2019) Maternal arrhythmia in structurally normal heart: prevalence and feasibility of catheter ablation without fluoroscopy. Pacing Clin Electrophysiol 42(12):1566–1572PubMed Li MM, Sang CH, Jiang CX, Guo XY, Li SN, Wang W, Zhao X, Tang RB, Long DY, Gao H, Dong JZ, Du X, Ma CS (2019) Maternal arrhythmia in structurally normal heart: prevalence and feasibility of catheter ablation without fluoroscopy. Pacing Clin Electrophysiol 42(12):1566–1572PubMed
55.
Zurück zum Zitat Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD (2015) Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 26(6):698–702PubMed Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD (2015) Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 26(6):698–702PubMed
Metadaten
Titel
Atrial fibrillation during pregnancy: a 9-month period with limited options
verfasst von
Konstantinos Iliodromitis, MD
Jacek Kociszewski, MD
Priv. Doz. Dr. Harilaos Bogossian, MD
Publikationsdatum
06.04.2021
Verlag
Springer Medizin
Erschienen in
Herzschrittmachertherapie + Elektrophysiologie / Ausgabe 2/2021
Print ISSN: 0938-7412
Elektronische ISSN: 1435-1544
DOI
https://doi.org/10.1007/s00399-021-00751-w

Weitere Artikel der Ausgabe 2/2021

Herzschrittmachertherapie + Elektrophysiologie 2/2021 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.